XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. The identity of the facility was not disclosed.
The Pharma Data
NOVEMBER 5, 2020
About Jubilant Cadista Pharmaceuticals Inc. Jubilant Cadista Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company in the United States devoted to discovery, manufacture, sale, and distribution of prescription generic pharmaceutical products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. The identity of the facility was not disclosed.
Pharmaceutical Technology
DECEMBER 22, 2022
This can include changes to materials and manufacturing, supply chain reviews; reduction in energy use or switches to renewables; recycling initiatives; and carbon offsetting. We are specifically looking at novelty, including companies launching products into new areas or innovation in the product’s design, manufacture or marketing.
XTalks
AUGUST 2, 2023
is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion the drug generated in 2021. every eight weeks for the 90 mg dose, according to the manufacturer. billion in 2022, a 23.43
Pharma in Brief
DECEMBER 3, 2023
The listed patents must be addressed by the manufacturer of a generic or biosimilar drug before its drug can receive a Notice of Compliance ( NOC ) and be sold in Canada. The early-working exception allows generic or biosimilar manufacturers to work a patented invention “for uses reasonably related” to obtaining regulatory approval.
XTalks
JUNE 8, 2022
Sandoz is a pioneering leader in generic pharmaceuticals and biosimilars, as Sandoz launched the world’s first biosimilar in Europe in 2006 and won the first biosimilar approval in the US in 2014. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar.
Expert insights. Personalized for you.
98 
Let's personalize your content